TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05645926

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention (PCI)
Description: Patients who underwent percutaneous coronary intervention (PCI), including percutaneous transluminal coronary angioplasty (PTCA), and coronary stent insertion

Intervention type: PROCEDURE
Intervention: Coronary artery bypass grafting (CABG)
Description: Patients who underwent coronary artery bypass grafting (CABG)
Study: NCT06006156

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implants placement
Description: surgery for placement of two one-piece trans gingival implants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implants placement
Description: surgery for placement of two one-piece trans gingival implants
Study: NCT05303116

Intervention type: DIAGNOSTIC_TEST
Intervention: Brainscope modified EEG and cognitive testing
Description: Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.

Intervention type: DIAGNOSTIC_TEST
Intervention: Brainscope modified EEG and cognitive testing
Description: Modified EEG performed using BrainScope device along with cognitive testing performed with BrainScope device and other surveys.
Study: NCT05133115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fostering Resilience in Adolescents at Risk
Description: The FRAK training was developed according to ecological framework, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of FRAK were established based on The Individual \& Environmental Resilience Model (IERM). Previous to the intervention, a systematic review and a meta-analysis on Resilience Interventions were performed.~Students will follow a training consisting of six 55-minute sessions: (1) introducing resilience, (2) self-esteem, (3) emotional strategies regulation, (4) social skills, (5) solving problems (6) community resources, social and peers' support.
Study: NCT05550168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser therapy
Description: The participants in the intervention group experienced a total of 7 session laser applications on their randomly determined molar region during the 12-week clinical trial period.
Study: NCT05502627

Intervention type: DRUG
Intervention: 0.25% lemon grass oil mouthwash
Description: 0.25% lemon grass oil mouth wash given twice daily for fourteen days to the patients of chronic periodontitis after scaling in experimental group and in control group only scaling was done.
Study: NCT05453851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: Undergo pancreatectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Planning
Description: Undergo IV autologous islet cell transplant
Study: NCT06527690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib/Abirate rone acetate fixed-dose combination
Description: Participants will receive niraparib/abiraterone acetate fixed-dose combination 100/500 mg 2 tablets once daily on days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib/Abirate rone acetate fixed-dose combination
Description: Participants will receive niraparib/abiraterone acetate fixed-dose combination 100/500 mg 2 tablets once daily on days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 5mg 2 tablets once daily on days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 5mg 2 tablets once daily on days 1-28 of each 28-day cycle.
Study: NCT05589324

Intervention type: BEHAVIORAL
Intervention: 3D-printed writing aids task
Description: Briefly explain how to wear assistive devices, confirm that the case understands how to operate, and conduct a writing task test. Situation includes no wearable assistive device,three pen placement designs with different angles (5 degrees, 20 degrees, and 30 degrees). Record the writing speed, legibility, posture, and satisfaction of the assistive device after each writing task, etc.
Study: NCT05887154

Intervention type: DEVICE
Group type: OTHER
Intervention: Microwave ablation
Description: microwave ablation
Study: NCT05767983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free milk
Description: Fat-free milk (500 mL, skim, 0%, Lactantia PurFiltre) will provide 180 kcal, 0 g fat, 26 g carbohydrate, and 18 g protein. Treatments matched for calories (180 kcal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-free yogurt
Description: Fat-free yogurt (242 g, vanilla, 0% Greek, Oikos) will provide 180 kcal, 0 g fat, 23.5 g carbohydrate, and 19.4 g protein. Treatments matched for calories (180 kcal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat cheese
Description: Low-fat cheese (60 g, mild marble cheddar, 40% less fat, Selection) will provide 180 kcal, 10 g fat, 2 g carbohydrate, and 16 g protein. Treatments matched for calories (180 kcal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice
Description: Fruit juice (450 mL, Fruité® Fruit Punch) will provide 180 kcal, 0 g fat, 46.8 g carbohydrate, and 0 g protein. Treatments matched for calories (180 kcal).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack skipping
Description: Water control treatment (no caloric contribution). Matched for volume (500 mL) to fat-free milk treatment.
Study: NCT05985863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard medical treatment
Description: standard medical treatment for ACLF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard medical treatment
Description: standard medical treatment for ACLF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard medical treatment
Description: standard medical treatment for ACLF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% human serum albumin in 0.9% saline (at week0, week1 and week2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC
Description: hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC
Description: hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week0, week1 and week2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hUC-MSC_Prolonged
Description: hUC-MSC (1.5×10\^8 cells/time, Peripheral IV, at week4 and week5)
Study: NCT06011863

Intervention type: PROCEDURE
Intervention: Thoracic Epidural Analgesia
Description: Thoracic Epidural Application: The epidural area will be accessed from the 7th (T7)-8th (T8) level of the thoracic vertebral midline with an 18 gauge (G) epidural needle using the hanging drip technique. After 2 ml of 2% lidocaine is administered and no spinal effect is observed, a mixture of morphine and local anaesthetic 3-4 mg morphine hydrochloride + 5 ml 0.5% bupivacaine + 2 ml 0.9% saline will be administered through the epidural needle at once and the epidural needle will be withdrawn and sterile dressing will be applied.

Intervention type: PROCEDURE
Intervention: Erector spinae plane block
Description: Before induction of anaesthesia, the patient is placed on the operating table and placed in a forward tilted position. Asepsis and antisepsis conditions are provided. The linear USG probe is moved approximately 2-3 cm lateral to the spinous process T5 - T6 level on the side to be operated. The trapezius, rhomboid major and erector spinae muscles will be identified to find the correct probe position. A 22 gauge 50 mm or 22 gauge 80 mm single shot nerve blocks needle will be inserted through the skin in a cranio-caudal direction. With the needle resting on the transverse process, the plane between the erector spinae muscle and the transverse process will be verified by hydrodissection with 5 ml saline solution. Then 20 ml of 0.25% bupivacaine will be injected. The ESP block will be considered successful if the local anaesthetic spreads linearly up to the T8 - T9 level. The patient will then be placed in the supine position and general anaesthesia will be administered.
Study: NCT06182059

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous peripheral nerve block
Description: continuous regional anesthesia in total knee replacement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous peripheral nerve block
Description: continuous regional anesthesia in total knee replacement
Study: NCT05876325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FINassist Patient
Description: The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FINassist Caregiver
Description: The FINassist intervention provides access to social, financial and legal services over the duration of 12 months or until issues are resolved
Study: NCT05128838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RISE (Reinvent, Integrate, Strengthen, Expand) Intervention
Description: Working one-on-one with the PI (a licensed occupational therapist (OT) and behavior change expert), participants will set goals and develop practical strategies in order to establish sustainable positive habits around lifestyle areas such as physical activity, nutrition, stress management, sleep, self-efficacy, and spiritual well-being. Motivational interviewing, cognitive behavioral therapy, and patient education will accompany intensive collaborative problem-solving and creation of accountability structures to create increased self-efficacy for health self-management. In summary, the RISE intervention includes three components: patient education, internalization of self-determination, and habit formation.
Study: NCT05555498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality glasses
Description: The intervention used are Virtual Reality glasses. The VR-glasses used are designed by SyncVR medical (Utrecht, the Netherlands), and are applicable specifically for medical use. By distracting the patients' cognition from the procedure, using images and sounds, the patient hopefully experiences less pain and anxiety. Women can choose between relaxation excersises and nature films
Study: NCT04897386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvalizumab
Description: Pemetrexed 850 mg, IV, Day1; Platinum 50mg / m2, IV, day1, once every 3 weeks, duvalizumab treatment, 1500mg, day1, a total of 4 cycles, once every 3 weeks. 4 cycles in total
Study: NCT04882696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-slip socks
Description: Patients will wear non-slip socks during their hospitalization
Study: NCT05952076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. infantis Bi-26
Description: A once-daily oral dose of Bi-26 will be provided to infants for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A once-daily oral dose of placebo maltodextrin will be provided to infants for 28 days
Study: NCT06029881

Intervention type: DEVICE
Intervention: Movesense MD
Description: This device can be attached to the skin (on the chest and center of mass) during sleep using a belt and adhesive electrodes.
Study: NCT05428956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Inhalation technique
Description: Single maximal inhalation with breath hold technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Inhalation technique
Description: Single maximal inhalation with breath hold technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal inhalation technique
Description: 5 tidal breaths technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal inhalation technique
Description: 5 tidal breaths technique
Study: NCT05466721

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrustoma C3
Description: The participant will use the device for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrustoma C3
Description: The participant will use the device for 14 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: Coloplast Alterna
Description: The participant will use the device for 14 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Alterna
Description: The participant will use the device for 14 days.
Study: NCT06077539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a selective a-2 adrenoceptor agonist, has sedative, analgesic, and anxiolytic effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: NMDA (N-methyl-D-aspartate) receptor antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: NMDA (N-methyl-D-aspartate) receptor antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9% NaCL
Description: saline will be given as bolus over 10 min then will be infused as maintenance by the same rate of the other groups
Study: NCT04895917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daratumumab and pomalidomide
Description: Patient eligible to enter the study will receive 6 cycles of 28 days of subcutaneous Daratumumab (1800 mg SC) and oral pomalidomide 4 mg from day 1 to day 21. During cycle 1 and 2, Daratumumab will be administered weekly at days 1, 8, 15, and 22 then from cycle 3 to 6, Daratumumab will be administered every other week at days 1 and 15.
Study: NCT01057836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neck endurance training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neck endurance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Study: NCT06030206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investigator-designed lung transplant education resource (Research Intervention)
Description: Participants will access the investigator-designed educational resource via their login to a secure website. After three months, participants will gain access to the publicly available website (attention control) and will have an additional three months of access to both of these resources.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly available transplant education resource (Attention-control)
Description: Participants will access the publicly available education resource via their login to a secure website. After three months, participants will gain access to the investigator-designed educational resource (research intervention) and will have an additional three months of access to both of these resources.
Study: NCT05523947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH32367
Description: Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8.~Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll 65 and 40 patients, respectively.
Study: NCT05602727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1942
Description: MK-1942 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1942
Description: MK-1942 oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT05434052

Intervention type: OTHER
Intervention: Turkish Validity and Reliability of The CIQ-R Scale
Description: The aim of this study is to adapt the Community Integration Questionnaire-Revised (CIQ-R)scale to Turkish society and to make its validity and reliability in Turkish. It has 18 questions. This study will be conducted with stroke patients. The patients will be sought to answer questionnaires during regular rehabilitation sessions.
Study: NCT06470828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-861
Description: Oral tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-861-matching placebo tablet.
Study: NCT04629833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC0518
Description: MC0518 will be intravenously infused immediately after thawing.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
Study: NCT06500468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillSense System
Description: The PillSense System consists of the PillSense Capsule, a small single use capsule that is safe for human consumption and PillSense Receiver, an external real-time monitor for data display. The PillSense Capsule is a minimally invasive, single use medical device designed to detect the presence of bleeding in the upper digestive tract, to aid with patient care. The PillSense Receiver collects and displays real-time information gathered by the PillSense Capsule within 10 minutes. The PillSense Receiver interprets the data and displays a result message Blood detected or No blood detected.
Study: NCT05096221

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single IV infusion of matching placebo.

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single IV infusion of matching placebo.
Study: NCT05786547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Per package dosing, tablet taken orally

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positively Smoke Free Mobile (PSF-M)
Description: Behavioral tobacco cessation intervention for people living with HIV, delivered via mobile phone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Brief cessation advice plus referral to local tobacco quitline
Study: NCT05440851

Intervention type: OTHER
Group type: OTHER
Intervention: Ultra-Protective Ventilation Facilitated by Extracorporeal Support
Description: Patients randomized to the intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.

Intervention type: OTHER
Group type: OTHER
Intervention: Lung-Protective Ventilation (LPV)
Description: Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.

Intervention type: OTHER
Group type: OTHER
Intervention: Lung-Protective Ventilation (LPV)
Description: Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.

Intervention type: OTHER
Group type: OTHER
Intervention: Driving Pressure-Limited Ventilation (DPL)
Description: Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.

Intervention type: OTHER
Group type: OTHER
Intervention: Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)
Description: Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.

Intervention type: DRUG
Group type: OTHER
Intervention: Early Cohort corticosteroid dose
Description: Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.

Intervention type: DRUG
Group type: OTHER
Intervention: Extended Cohort corticosteroid dose
Description: Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).

Intervention type: DRUG
Group type: OTHER
Intervention: Usual care without routine corticosteroids
Description: Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.

Intervention type: DRUG
Group type: OTHER
Intervention: Usual care without extending corticosteroids
Description: Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
Study: NCT06427889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canoderm
Description: humectant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oviderm
Description: humectant + antimicrobial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decubal
Description: Non-humectant
Study: NCT05645341

Intervention type: DIAGNOSTIC_TEST
Intervention: screening system for ocular surface malignant tumors
Description: Develop an intelligent screening system for ocular surface malignant tumors, apply it to the mobile terminal for real-world verification and large-scale general screening, and test its effect on assisting doctors in the diagnosis and treatment of rare diseases.